8 Foods You Should Be Eating Every Week If You Have High Blood Pressure, According to Dietitians
We're often told to avoid sodium, yet many foods are naturally rich in blood pressure–lowering nutrients.
Potassium, magnesium, calcium, fiber and omega-3 fats may help reduce blood pressure.High blood pressure, or hypertension, affects roughly half of American adults. While many people need medication to control this condition, regularly eating certain foods can also help lower your blood pressure—no prescription required.
So, what are these power foods? To find out, we asked dietitians the best blood pressure–lowering foods to add to your weekly rotation. Get out your pen and paper (or smartphone!) because you're going to want to make sure these eight foods are at the top of your shopping list.
Bananas are nutrient gold mines when it comes to better blood pressure, says Natalie Rizzo, M.S., RDN. For starters, she says, bananas are a good source of potassium. This mineral helps lower blood pressure by decreasing the stress on blood vessel walls caused by eating too much sodium. Even though most of us consume too much sodium, few of us get enough potassium. That's where bananas come in. One medium banana provides roughly 420 milligrams of potassium, or 9% of the Daily Value.
Bananas also provide fiber, which helps lower blood pressure by producing compounds called short-chain fatty acids that help relax blood vessels and improve blood flow. Yet, like potassium, most of us don't consume nearly enough fiber. One medium banana delivers an easy 3 grams of fiber, which is roughly 11% the 28-gram DV.
If beets aren't already on your list of heart-healthy foods, they should be! These deep purple veggies contain dietary nitrates, compounds your body converts to a blood pressure–lowering nitric oxide. That's not all. They give you 442 mg of potassium per cup (9% of the DV). So, toss some in your next salad. Or, if you want even more blood pressure–lowering power, pour a glass of beet juice. Research has shown it can significantly reduce systolic blood pressure, the blood pressure reading most closely related to heart disease risk.
Soy foods like edamame are powerful players when it comes to lowering blood pressure. The proof is so strong that one systematic review and meta-analysis of 17 studies found that eating soy foods can significantly reduce both systolic and diastolic blood pressure.
If you're wondering what makes edamame so effective, the answer may lie in their nutrient density. One cup of shelled edamame packs an impressive 8 grams of fiber. That's more than a quarter of your daily requirement. It also contains 14% of the DV for potassium, plus other blood pressure–lowering minerals like magnesium and calcium.
'Regular consumption of pistachios has been shown in several studies to help reduce blood pressure,' says Kelly Jones, M.S., RD, CSSD. One reason is their fiber. 'Per 1-ounce serving, pistachios provide 3 grams of fiber, a nutrient emphasized by the DASH diet,' says Jones., If you haven't heard of the DASH diet before, it's a blood pressure–lowering eating pattern backed by decades of research.
In addition to fiber, pistachios also contain a potent blood pressure–lowering cocktail of potassium, magnesium, calcium, antioxidants and plant protein.
'Although potatoes get a bad reputation, they are full of nutrition and are a good source of potassium,' says Rizzo. 'Since potassium works with sodium to regulate blood pressure, increasing potassium intake is another strategy to help improve blood pressure,' adds Jones.
One medium potato delivers 952 mg of potassium. That's 20% of your daily requirement and more than double the amount you'd get from a medium banana.
Pulses like beans, lentils and dried peas are an integral part of the DASH diet. Like many other foods on this list, they're rich in potassium and plant protein. But don't just munch on them for their blood pressure benefits. Research has also shown that pulses may lower cholesterol and inflammation and protect against heart attack and cardiovascular disease.
You may have heard that omega-3-rich fatty fish like salmon are fantastic foods for heart health. One reason is their favorable impact on blood pressure. Research has found that the long-chain omega-3 fats docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) help relax the muscles of the blood vessel walls. This process, known as vasodilation, allows blood to move easily throughout the body, ultimately reducing blood pressure.
Yogurt isn't just great for your gut health. One study found that people with hypertension who frequently consumed yogurt had lower systolic blood pressure. This study didn't find that yogurt had the same impact on people with normal blood pressure. However, another study found that people with healthy blood pressure who regularly ate yogurt were less likely to develop hypertension. While more research is needed, yogurt boasts a long list of health benefits, including lower cholesterol levels and better heart and digestive health. So, tossing a few containers into your shopping cart can do all kinds of good things for your body.
Calcium. Calcium is a key mineral for healthy blood pressure. It is believed to work by helping blood vessels relax and favorably impacting hormones that regulate blood pressure. In addition to yogurt, you can get calcium from dairy milk, fortified plant milks, cheese, sardines and salmon with bones.
Fiber. Research shows that the more soluble fiber people eat, the lower their blood pressure tends to be. You'll find soluble fiber in oats, barley, beans and legumes, fruits, vegetables, nuts and seeds.
Magnesium. This tiny but mighty mineral plays a role in more than 300 enzymatic reactions in your body. So, it should come as no surprise that it's instrumental for healthy blood pressure. Magnesium-rich foods include pumpkin and chia seeds, almonds, cashews, peanuts, spinach, edamame and soy milk.
Long-Chain Omega-3 Fatty Acids. DHA and EPA are found in fatty fish like salmon, mackerel, herring, sardines and anchovies. They promote heart health by regulating blood pressure and reducing inflammation. If you're not a fish eater, speak to your health care provider to find out if a supplement is right for you.
Potassium. We often hear that people with high blood pressure should limit sodium, says Jones. And they should! However, the opposite is true when it comes to potassium, which works to offset some of sodium's blood pressure–raising action. You'll find it in every food on this list!
Whether you have high blood pressure or simply want to prevent it, there's a long list of foods that can keep your blood pressure in a healthy range. These include bananas, beets, edamame, pistachios, potatoes, pulses, salmon and yogurt. These tasty, nutrient-packed foods are rich in blood pressure–regulating nutrients like potassium, magnesium, calcium, fiber and omega-3 fatty acids. Plus, they're convenient and accessible. No wonder dietitians are such big fans! So, when you make your next grocery run, toss any (or all!) of them in your cart. Because better blood pressure is as much about what you do eat as what you don't.
Read the original article on EATINGWELL
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
CELFULL Unveils Celfavor NADH Microcapsules: A Breakthrough in Stability That Reshapes the Anti-Aging Industry
CORAL SPRINGS, FL / / July 4, 2025 / CELFULL, a biotechnology company with over 25 years of expertise in anti-aging science, has announced a major breakthrough in longevity innovation: the global launch of Celfavor® NADH Microcapsules, a patented delivery system that resolves the century-long challenge of NADH instability. Journal papers related to NADH This revolutionary technology-protected by seven international invention patents across the U.S., China, Japan, Canada, and South Korea-delivers unprecedented improvements in stability, bioavailability, and targeted delivery, marking a new era in anti-aging therapeutics known as the "Microcapsule Age." To accelerate research across the globe, CELFULL has also launched its Global Research Sharing Program, offering free access to the Celfavor® NADH raw material to scientific institutions worldwide. Celfavor®NADH The only effective NADH - Celfavor ® NADH "The discovery of the therapeutic effect of stabilized NADH is more important to humankind than the discovery of antibiotics." noted Nobel Laureate Sir John Eccles, underscoring the importance of this innovation. NADH stands for "nicotinamide adenine dinucleotide (NAD) + hydrogen (H), often dubbed the "King of Anti-Aging Molecules," plays a central role in mitochondrial energy production, antioxidant defense, and the activation of longevity proteins. However, its inherent instability-sensitive to heat, light, oxygen, and stomach acid-has severely limited its clinical applications. Conventional NADH degrades by over 70% in one month at room temperature and must be stored at -20°C, making practical use difficult. 7 patents have been certified CELFULL's research team, led by its AI-powered Multi-Target Anti-Aging Institute, spent over a decade solving this problem. The result: Celfavor® NADH Microcapsules, a proprietary technology featuring 250-350μm microcapsules that protect NADH with a multi-core soluble shell made from food-grade materials. In stability tests simulating harsh conditions (40°C / 75% RH), traditional NADH retained only 3.5% of its activity after six months. By contrast, Celfavor® NADH maintained 98.3% activity-demonstrating over 6x shelf-life extension, even without refrigeration or light shielding. The stability of Celfavor® NADH microspheres The Celfavor® NADH Microcapsule system delivers innovation across four dimensions: 1. Enhanced Stability: Microcapsules shield NADH from air, moisture, light, and stomach acid, preserving its full potency in gastrointestinal conditions for up to 4 hours. 2. Targeted Release: Using AI-optimized wall material, the system enables "zero release in the stomach and sustained release in the intestine." Simulated intestinal studies show 24-hour continuous release, extending absorption time by 5-8x. 3. Superior Bioavailability: In human trials, a daily dose of 40mg led to a 98% increase in blood NAD⁺ levels, a 3.2x improvement over regular NADH. Performance also surpassed other NAD⁺ precursors like NMN and NR. 4. Formulation Flexibility: Unlike unstable NADH, Celfavor® NADH can be safely co-formulated with vitamins, coenzymes, or peptides in single or multi-ingredient capsules. Celfavor ® NADH microsphere advanced technology surpasses others Celfavor® NADH Microcapsules have been granted seven invention patents and passed all 12 safety evaluations, including cytotoxicity and long-term toxicity tests. It is currently the only NADH raw material globally to pass full-spectrum safety certification. The only globally certified raw material for toxicology and safety experiments "We are not just creating better products-we are building a platform for the future of longevity," said Dr. Juliane Hitzel, CEO of CELFULL. "With this microcapsule technology, we're launching new delivery systems for vitamins, peptides, and more. And by sharing our raw materials with global researchers, we're fostering a collaborative ecosystem that accelerates anti-aging science." From solving the NADH stability problem to advancing intelligent delivery systems, CELFULL's innovation signals a major milestone in human longevity science. As the Celfavor® NADH Microcapsule technology rolls out globally, the anti-aging industry enters a new chapter-one defined by precision, efficiency, and collaboration. For business cooperation or research partnerships, please contact:maggie@ | Email: maggie@ SOURCE: CELFULL View the original press release on ACCESS Newswire Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data


Washington Post
44 minutes ago
- Washington Post
Asking Eric: After ugly comments, brother invites himself to party
Dear Eric: Nearly eight months ago, my 81-year-old brother lashed out saying hateful and hurtful things about our youngest sister. At the time, I suspected he was drunk and probably frustrated from the repeated episodes of our sister's illnesses and problems, some of which have been caused by her own serious eating disorder, depression and occasional binge drinking.
Yahoo
an hour ago
- Yahoo
Maximise Your Portfolio's Returns with These 3 US Healthcare Stocks
With persistent macro uncertainty and shifting market trends, healthcare remains one of the most defensive and fundamentally sound sectors for investors. The US healthcare industry continues to deliver both stability and long-term growth potential. In the latter half of 2025, these three healthcare stocks emerge as top picks for their compelling mix of innovation and favourable industry trends. Johnson & Johnson (J&J) is a global healthcare company with its core businesses in innovative medicine and MedTech. In the first quarter of 2025 (1Q 2025), J&J reported 2.4% year-on-year (YoY) increase in revenue, bringing in US$21.9 billion. This growth can be attributed to a strong revenue growth of 4.2% YoY in innovative medicine. A key driver for the rise is the 20.4% YoY in revenue growth in the oncology segment. This increase is due to medicine such as DARZALEX and ERLEADA experiencing share gains amid market growth.J&J's MedTech division recorded a strong 4.1% YoY revenue growth. The cardiovascular segment led this jump in revenue with a 17% YoY revenue growth. This growth is due to strong global procedure volumes and successful new product launches. The firm's internal forecast for sales of its key products by 2027/2028 is also higher than current market estimates. For instance, its pipeline product, the intravesical drug releasing system, is forecasted to have three times the product sales compared to current market estimates by 2027/ presents an opportunity for investors to capitalise on the potential upside which is not yet priced into the stock. This upside will be driven by J&J's internal forecasts, which signal confidence in its operations. Thermo Fisher is a top name in biopharmaceutical research, particularly in drug discovery and 1Q 2025, Thermo Fisher reported revenue of US$10.36 billion, along with organic revenue growth of 1% YoY. The firm's net profits climbed 13.5% YoY to US$1.5 billion in 1Q 2025. This strong growth was supported by the increased operational efficiencies with the partnership with the Chan Zuckerberg Institute for Advanced Biological partnership pioneers new technologies for improved human cell visualisation, providing scientists with better data insights and accelerating research cycles. In February 2025, Thermo Fisher also announced a US$4.1 billion acquisition of Solventum's Purification & Filtration Purification & Filtration business offerings enhance Thermo Fisher's current bioproduction services. This acquisition boosts Thermo Fisher's biologics production capabilities, thereby improving productivity. This deal also opens opportunities to cross-sell filtration and purification solutions alongside existing bioprocessing offerings. These developments demonstrate an effective strategic fit and may result in service margin expansion. UnitedHealth Group runs two primary businesses – UnitedHealthcare for healthcare insurance plans and Optum for technology-based healthcare services. UnitedHealth Group reported a 9.8% YoY increase in revenue in 1Q 2025, reaching US$109.6 billion. The company's net margin also improved to 5.7% in the same quarter. The previous year's quarter saw a net loss margin of 1.4%. The better performance was attributed to a strong performance for both UnitedHealthcare and Optum. In 1Q 2025, UnitedHealthcare's revenue grew by 12.2% YoY to US$84.6 billion. This growth was driven by a rise of 700,000 in the number of self-funded commercial plans sold. Another factor was the increased participation in senior and community-based offerings with 545,000 new members. In the same period, Optum saw an increase in revenue of 4.6% YoY to US$63.9 billion. This rise is led by a growth of Optum Rx which had an increase of 13 million scripts from new clients and deepening of existing relationships compared to 2024. Optum Insight also introduced artificial intelligence claim processing tools which increase productivity by over 20%. Moving forward, Optum Health announced its continued expansion of value-based care to serve 650,000 new patients in 2025. As the healthcare landscape transforms, these three companies offer stand-out opportunities amid uncertain markets. With these companies' blend of innovation and strong fundamentals, they provide a defensive anchor along with room for growth. These three stocks are well-positioned to deliver meaningful returns. It's a good idea to consider adding this trio into your buy watchlist of growth stocks. Generative AI is reshaping the stock market, but not in the way most investors think. It's not just about which companies are using AI. It's about how they're using it to unlock new revenue, dominate their markets, and quietly reshape the business world. Our latest FREE report 'How GenAI is Reshaping the Stock Market' breaks the hype down, so you can invest with greater clarity and confidence. Click here to download your copy today. Follow us on Facebook, Instagram and Telegram for the latest investing news and analyses! Disclosure: Gabriel Lim does not own shares in any of the companies mentioned. The post Maximise Your Portfolio's Returns with These 3 US Healthcare Stocks appeared first on The Smart Investor. Sign in to access your portfolio